China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.

Employees

166

Sector

Healthcare Facilities & Services

More about the company

Quotes

Date	Price	Change	Volume
26-09-22	HK$0.5600	-5.08%	160,000
26-09-21	HK$0.5900	-0.84%	200,000
26-09-18	HK$0.5950	0.00%	55,000
26-09-17	HK$0.5950	-0.83%	180,000
26-09-16	HK$0.6000	0.00%	85,000

Delayed Quote Hong Kong S.E.

More quotes

Market Closed - Hong Kong S.E. 04:08:13 2026-09-22 EDT			5-day change	1st Jan Change
0.5600 ^HKD	-5.08%		-11.11%	-29.11%

08-28	China Biotech Services Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-12	China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2026	CI

Market Cap	546M 69.66M 60.88M 57.22M 52.21M 98M 6.66B 98.01M 687M 265M 3.4B 262M 256M 10.96B	P/E 2024	-2.49x	P/E 2025	-11.2x
Enterprise Value	929M 118M 104M 97.3M 88.79M 167M 11.33B 167M 1.17B 451M 5.78B 445M 435M 18.64B	EV / Sales 2024	9.45x	EV / Sales 2025	15.7x
Free-Float	35.46%	Yield 2024 *	-	Yield 2025	-

08-28	China Biotech Services Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-12	China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2026	CI
08-11	China Biotech Services Holdings Limited and Stella Pharma Corporation Enter Master Collaboration Agreement for Commercialisation of BNCT Drug	CI
08-03	China Biotech Services Holdings Limited's Japan, Pengbo Medical Technology Co., Ltd. Present of Initial Follow-Up Findings of Boron Neutron Capture Therapy At the 22Nd Congress on Neutron Capture Therapy	CI
05-18	China Biotech Services' unit disposes entire stake in PHC Medical Diagnostic Centre, others	RE
04-30	China Biotech Services says He Xun resigns as executive director	RE
04-30	China Biotech Services Holdings Limited Announces Resignation He Xun as Executive Director, Effective May 1, 2026	CI
04-28	China Biotech Services Holdings Limited Auditor Raises 'Going Concern' Doubt	CI
03-27	China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-06	China Biotech Services expects FY net loss of not more than HK$100 million	RE
03-06	China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025	CI
02-19	China Biotech Services Holdings Limited announced that it has received HKD 272.3 million in funding from Wealth Strategy Holding Ltd	CI
12-29	China Biotech Services to issue convertible bonds	RE

23-01-10	China Biotech Services subsidiary AMDL nominated as Top Clinical Laboratory Services Company in APAC 2022 and receives CAP Accreditation Certificate	AQ
22-06-24	Sumitomo Heavy Industries, Ltd. - Notice Regarding Our First Overseas Introduction of BNCT in the Hainan Medical Tourism Pilot Zone, China	AQ
21-08-09	China Biotech Services : AMDL, a Subsidiary of China Biotech Services, is Exclusively Licensed to Distribute FDA Approved Lung & Colon Cancer Companion Diagnostic Assay in Several Asian Regions Including China	AQ
21-06-28	China Biotech Services (8037.HK): Confident shareholders are taking long on their books in anticipation of promising results to be generated from the double engines of growth on cell therapy and precision diagnostic businesses	AQ
21-01-28	China Biotech Services : Shanghai Longyao Chief Scientist Professor Xuanming Yang published a research article on optimizing CAR-T cells function with independently expressed full-length OX40	AQ

China Biotech Services Holdings Limited Stock

Stocks

8037

BMG2152F1014

Healthcare Facilities & Services

Valuation: China Biotech Services Holdings Limited

Chart: China Biotech Services Holdings Limited

Latest news: China Biotech Services Holdings Limited

Press Releases: China Biotech Services Holdings Limited

Quotes and Performance

Price Extremes

Managers and Directors: China Biotech Services Holdings Limited

Latest insider transactions

Other Healthcare Facilities & Services

Financials

Company Profile

Quotes

1 day	-5.08%
1 week	-11.11%
Current month	-1.75%
1 month	-9.68%
3 months	-6.67%
6 months	-26.32%
Current year	-29.11%

1 week	0.55	0.62
1 month	0.5	0.66
Current year	0.3	0.92
1 year	0.3	1.08
3 years	0.25	1.33
5 years	0.25	2.64
10 years	0.16	2.64

Manager	Title	Age	Since
Eddy Lai DFI	Director of Finance/CFO	-	-
Xiao Lin Liu CMP	Compliance Officer	55	2022-05-25
Xuan ming Yang CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Guo Xiang Yan BRD	Director/Board Member	60	2017-08-06
Song Huang BRD	Director/Board Member	44	2017-09-14
Xiao Lin Liu CHM	Chairman	55	2017-08-27

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/30/26	Xiao Lin Liu	Other	Chairman	3,600,000	0.3690%
9/2/24	Xun He	Other	Director	3,220,000	0.3300%
6/13/24	Hoi Yam Chui	Other	Director	5,000,000	0.5191%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA BIOTECH SERVICES HOLDINGS LIMITED	-5.08%	-11.11%	-47.66%	-9.68%	73.38M
CVS HEALTH CORPORATION	+0.09%	-7.36%	+16.52%	+23.04%	112B
HCA HEALTHCARE, INC.	+2.35%	+2.70%	+6.88%	+72.54%	92.22B
FRESENIUS SE & CO. KGAA	-0.78%	+0.47%	-2.05%	+47.89%	29.13B
QUEST DIAGNOSTICS INCORPORATED	-4.28%	-6.11%	+25.61%	+87.87%	27.03B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.09%	-1.64%	-9.36%	-3.03%	21.22B
TENET HEALTHCARE CORPORATION	+0.61%	+0.64%	+35.28%	+287.60%	21.01B
REDE D'OR SÃO LUIZ S.A.	-0.84%	+2.33%	-9.37%	+43.07%	16.26B
FRESENIUS MEDICAL CARE AG	+1.16%	-1.21%	-9.03%	-6.36%	11.81B
DAVITA INC.	+1.00%	-3.42%	+40.59%	+86.79%	11.63B
Average	-0.58%	-1.66%	+4.74%	+62.97%	34.24B
Weighted average by Cap.	+0.33%	-2.65%	+11.30%	+60.32%

	2024	2025
Net sales	70.51M 8.99M 7.86M 7.38M 6.74M 12.65M 859M 12.65M 88.61M 34.19M 439M 33.76M 33.02M 1.41B	73.5M 9.37M 8.19M 7.7M 7.02M 13.18M 896M 13.18M 92.38M 35.65M 457M 35.19M 34.42M 1.47B
Net income	-198M -25.26M -22.08M -20.75M -18.93M -35.54M -2.41B -35.54M -249M -96.09M -1.23B -94.87M -92.79M -3.98B	-68.78M -8.77M -7.66M -7.2M -6.57M -12.33M -838M -12.34M -86.44M -33.35M -428M -32.93M -32.21M -1.38B
Net Debt	169M 21.54M 18.82M 17.69M 16.14M 30.29M 2.06B 30.3M 212M 81.92M 1.05B 80.87M 79.1M 3.39B	383M 48.81M 42.65M 40.09M 36.58M 68.66M 4.67B 68.67M 481M 186M 2.38B 183M 179M 7.68B